Rua Bioscience Confirms First International Order

Rua Bioscience Limited (NZX: RUA) formally announced today that it has received its first order via its German distributor Nimbus Health, marking a significant commercial milestone for the export-focused company.

Managing Director, Anna Stove, says “Receiving this order for dried flower from Nimbus signifies just how close we are to cementing export revenues and providing German patients with a sustainable supply of Rua medicines”.

The order is for Rua’s high THC flower, which has been developed through an extensive R&D programme by Cann Group, Rua’s Australian manufacturing, supply and technical services partner. In Germany, medicinal dried cannabis flower is prescribed mainly for pain patients (70%), and cannabis flowers with a THC content of greater than 20% make up 77% of cannabis flower prescriptions (1).

“At its launch, we believe Rua’s flower will be one of the highest THC dried flower medicines on the market, which will give Rua a significant competitive advantage,” she says.

While Rua looks to global markets, the company remains committed to its connection to Te Tairāwhiti and to patients across New Zealand having launched its first product in Aotearoa in April.

“The kaupapa to give back to the community will always be in our DNA and entering global markets will secure meaningful revenue so we can continue prioritising sustainable economic development in the Ruatorea and East Coast communities,” says Stove.